-
Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
-
A 71-year-old retired police officer was admitted through the emergency room with right upper quadrant pain and low-grade fever.
-
Limited data are available to guide the decision between up-front allogeneic hematopoietic cell transplantation (HCT) or imatinib on long-term outcomes for accelerated phase chronic myelogenous leukemia (CML).
-
In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy.
-
-
In this issue: Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
Among 701 women with chronic pelvic pain (CPP), 22% were affected by clinical depression. After undergoing either surgery (including hysterectomy) or non-surgical alternatives, response to the therapy was found to be independent of the presence of depression.
-
The investigators prospectively enrolled and followed a cohort of 97 teenagers before, and 6, 12, and 18 months after starting depot medroxyprogesterone acetate (DMPA).
-
Endometriosis is a common disorder in reproductive-age women and has been associated with an increased risk for development of invasive ovarian cancer.